HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
NCT02836548
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Skin Neoplasms
Interventions
DRUG:
Vorinostat
Sponsor
The Netherlands Cancer Institute